EA039074B1 - Жирные кислоты и их конъюгаты с биомолекулами - Google Patents

Жирные кислоты и их конъюгаты с биомолекулами Download PDF

Info

Publication number
EA039074B1
EA039074B1 EA201692466A EA201692466A EA039074B1 EA 039074 B1 EA039074 B1 EA 039074B1 EA 201692466 A EA201692466 A EA 201692466A EA 201692466 A EA201692466 A EA 201692466A EA 039074 B1 EA039074 B1 EA 039074B1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugate
hgdf15
disease
fatty acid
linker
Prior art date
Application number
EA201692466A
Other languages
English (en)
Russian (ru)
Other versions
EA201692466A1 (ru
Inventor
Дэвид Венингер Барнс
Кен Ямада
Чиквенду Ибебунджо
Алокеш Дуттарой
Луиз Клэр Кирман
Александра Маршалл Брюс
Эйми Ричардсон Юзера
Фредерик Зекри
Цзюнь Юань
Чанган Лоу
Аарон Кантер
Авируп Боуз
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53491695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA039074(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201692466A1 publication Critical patent/EA201692466A1/ru
Publication of EA039074B1 publication Critical patent/EA039074B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/18—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon triple bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/285—Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
EA201692466A 2014-06-23 2015-06-18 Жирные кислоты и их конъюгаты с биомолекулами EA039074B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462015862P 2014-06-23 2014-06-23
US201462082327P 2014-11-20 2014-11-20
US201562107016P 2015-01-23 2015-01-23
PCT/US2015/036328 WO2015200078A1 (en) 2014-06-23 2015-06-18 Fatty acids and their use in conjugation to biomolecules

Publications (2)

Publication Number Publication Date
EA201692466A1 EA201692466A1 (ru) 2017-04-28
EA039074B1 true EA039074B1 (ru) 2021-11-30

Family

ID=53491695

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692466A EA039074B1 (ru) 2014-06-23 2015-06-18 Жирные кислоты и их конъюгаты с биомолекулами

Country Status (36)

Country Link
US (4) US10588980B2 (OSRAM)
EP (2) EP3157571B1 (OSRAM)
JP (5) JP6636959B2 (OSRAM)
KR (2) KR20230056796A (OSRAM)
CN (3) CN114099693A (OSRAM)
AP (1) AP2016009585A0 (OSRAM)
AU (1) AU2015280351C1 (OSRAM)
CA (1) CA2953480A1 (OSRAM)
CL (1) CL2016003281A1 (OSRAM)
CR (1) CR20160596A (OSRAM)
CU (1) CU24455B1 (OSRAM)
CY (1) CY1125006T1 (OSRAM)
DK (1) DK3157571T3 (OSRAM)
EA (1) EA039074B1 (OSRAM)
EC (1) ECSP17004665A (OSRAM)
ES (1) ES2905479T3 (OSRAM)
GT (1) GT201600263A (OSRAM)
HR (1) HRP20220152T1 (OSRAM)
HU (1) HUE057845T2 (OSRAM)
IL (1) IL248990B (OSRAM)
JO (1) JO3813B1 (OSRAM)
LT (1) LT3157571T (OSRAM)
MA (1) MA40278A (OSRAM)
MX (1) MX367520B (OSRAM)
MY (1) MY193993A (OSRAM)
PE (1) PE20171095A1 (OSRAM)
PH (1) PH12016502294B1 (OSRAM)
PL (1) PL3157571T3 (OSRAM)
PT (1) PT3157571T (OSRAM)
RS (1) RS62907B1 (OSRAM)
SG (2) SG10201912965TA (OSRAM)
SI (1) SI3157571T1 (OSRAM)
TN (1) TN2016000558A1 (OSRAM)
TW (3) TWI792596B (OSRAM)
UY (1) UY36186A (OSRAM)
WO (1) WO2015200078A1 (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2015017710A1 (en) 2013-07-31 2015-02-05 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP2017537926A (ja) 2014-12-04 2017-12-21 ノバルティス アーゲー Ｋｌｏｔｈｏ変種ポリペプチドを使用する方法および組成物
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
JP6892433B2 (ja) 2015-04-03 2021-06-23 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 十分に安定化された非対称ｓｉｒｎａ
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
JP7749201B6 (ja) 2016-01-31 2025-10-21 ユニバーシティー オブ マサチューセッツ 分岐オリゴヌクレオチド
BR112018072034A2 (pt) 2016-05-24 2019-02-12 Novo Nordisk A/S compostos mic-1 e usos dos mesmos
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
WO2018031933A2 (en) * 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
SG11201906735RA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
RU2019135845A (ru) 2017-04-11 2021-05-11 Ридженерон Фармасьютикалз, Инк. Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b)
ES2867807T3 (es) 2017-04-24 2021-10-20 Igm Group B V Proceso para la preparación de cetonas a-funcionalizadas
CA3063872A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
US10844377B2 (en) 2017-06-23 2020-11-24 University Of Massachusetts Two-tailed self-delivering siRNA
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
EP3727423B1 (en) 2017-12-22 2024-05-22 Novartis AG Treatment of metabolic disorders with fgf21 variants
US12359201B2 (en) 2018-03-21 2025-07-15 Regeneron Pharmaceuticals, Inc. 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
AU2019253462B2 (en) 2018-04-09 2025-04-24 Amgen Inc. Growth differentiation factor 15 fusion proteins
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
AU2019317813A1 (en) 2018-08-10 2021-02-11 Novartis Ag GFRAL extracellular domains and methods of use
KR20210093227A (ko) 2018-08-10 2021-07-27 유니버시티 오브 매사추세츠 Snp를 표적화하는 변형된 올리고뉴클레오티드
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
TWI869213B (zh) * 2018-09-19 2025-01-01 美商Ionis製藥公司 Pnpla3表現之調節劑
CR20210193A (es) 2018-10-22 2021-06-15 Janssen Pharmaceutica Nv Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas
JP2022513626A (ja) 2018-11-26 2022-02-09 ノバルティス アーゲー Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
WO2020150636A1 (en) 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
CA3136969A1 (en) * 2019-04-23 2020-10-29 Lg Chem, Ltd. Fusion polypeptide comprising fc region of immunoglobulin and gdf15
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
EP3999103A4 (en) * 2019-07-19 2023-11-22 Inari Agriculture Technology, Inc. GENOMIC EDITING FOR ENHANCED HOMOLOGY-DIRECTED REPAIR
MX2022001710A (es) 2019-08-09 2022-05-10 Univ Massachusetts Oligonucleótidos modificados químicamente dirigidos a los snp.
KR20220058578A (ko) 2019-09-03 2022-05-09 아크투루스 쎄라퓨틱스, 인크. 치료 활성 접합체의 아시알로당단백질 수용체 매개 전달
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
EP4054521A1 (en) 2019-11-04 2022-09-14 Ferring B.V. Intranasal administration of merotocin for improving lactation
BR112022009976A2 (pt) * 2019-11-26 2022-10-04 Dtx Pharma Inc Composto compreendendo um ácido nucleico e motivo de extensão de meia-vida
WO2021126990A1 (en) * 2019-12-16 2021-06-24 The Scripps Research Institute Oxytocin derivatives with improved properties
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
JP2023509991A (ja) * 2020-01-13 2023-03-10 シンアフィックス ビー．ブイ． 抗体及び免疫細胞エンゲージャーのコンジュゲート
CN115666656A (zh) * 2020-01-13 2023-01-31 西纳福克斯股份有限公司 通过环加成双侧功能化抗体
WO2021144314A1 (en) * 2020-01-13 2021-07-22 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
WO2022245183A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
EP4398939A1 (en) * 2021-09-10 2024-07-17 Guardian Therapeutics, LLC Fatty acid conjugates of nucleic acids
CN113582832B (zh) * 2021-09-13 2024-01-26 深圳瑞德林生物技术有限公司 一种长链二酸的制备方法
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114740105B (zh) * 2022-03-17 2023-11-07 重庆医药高等专科学校 一种脯氨酸和n-甲基脯氨酸的液相色谱分离检测方法及其应用
WO2023196754A2 (en) * 2022-04-08 2023-10-12 University Of North Texas Health Science Center At Fort Worth Treatment for reducing or preventing tissue fibrosis
CN114891086B (zh) * 2022-06-01 2024-03-26 恺佧生物科技(上海)有限公司 一种生物素标记的gdf15的复性方法
CA3262911A1 (en) * 2022-08-01 2024-02-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Conjugates of fatty acid-D-amino acids as anaplerotic compounds intended for use in the treatment of propionic acidemia, methylmalonic aciduria, and metabolic energy disorders
CN115575539B (zh) * 2022-10-12 2025-04-18 南方医科大学珠江医院 一种生物标本中短链脂肪酸及其羟基化衍生物的检测方法
CN116789764B (zh) * 2023-05-30 2025-01-03 北京悦康科创医药科技股份有限公司 一种抗冠状病毒多肽的制备方法
CN116466010B (zh) * 2023-06-15 2023-08-25 四川普锐特药业有限公司 一种用于脂质纳米粒中多种脂质组分定量检测的方法
WO2025049634A1 (en) * 2023-08-29 2025-03-06 Ganna Bio, Inc. Glycan conjugate compositions and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083505A1 (en) * 2012-11-30 2014-06-05 Novartis Ag Methods for making conjugates from disulfide-containing proteins
WO2015006728A2 (en) * 2013-07-11 2015-01-15 Usera Aimee Site-specific chemoenzymatic protein modifications
WO2015013169A2 (en) * 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015013168A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043871A (en) * 1956-09-03 1962-07-10 Ruhrchemie Ag Production of heptadecanedicarboxylic acid-1, 17
GB2124618A (en) 1982-06-11 1984-02-22 Nat Res Dev Aliphatic hydroxy amides
US4517105A (en) 1983-03-07 1985-05-14 Aluminum Company Of America Metalworking lubricant composition containing a novel substituted malonic acid diester
US4582927A (en) 1984-04-04 1986-04-15 Frito-Lay, Inc. Synthetic cooking oils containing dicarboxylic acid esters
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE69120645T2 (de) 1990-12-26 1997-02-13 Ricoh Kk Reversible wärmeempfindliche Aufzeichnungszusammensetzung, Aufzeichnungsmedium, Aufzeichnungsverfahren und Anzeigevorrichtung, die das Aufzeichnungsmedium verwendet
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
FR2735131B1 (fr) 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
ATE423788T1 (de) 1995-06-22 2009-03-15 St Vincents Hosp Sydney Neues tgf-beta-ahnliches cytokin
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
BR9711763A (pt) 1996-09-11 1999-08-24 Ortho Mcneil Pharm Inc Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
CA2313246A1 (en) 1997-12-24 1999-07-08 Takeda Chemical Industries, Ltd. Polypeptide, their production and use
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6297400B1 (en) 1999-07-02 2001-10-02 The Clorox Company Synthesis of a tetraamido macrocycle ligand from a novel diamidodiol
US20020045170A1 (en) 2000-04-06 2002-04-18 Wong Gordon G. Polynucleotides encoding novel secreted proteins
AU2001250182B2 (en) 2000-04-20 2006-06-08 St Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
US20030166903A1 (en) 2001-04-27 2003-09-04 Anna Astromoff Genes associated with vascular disease
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
PT1638963E (pt) 2003-05-20 2009-11-18 Novartis Ag Heterociclos de azoto n-acilado como ligandos de receptores activados pelo proliferador peroxissomal
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
JP2007522803A (ja) 2004-01-14 2007-08-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ペルオキシソーム増殖因子活性化受容体アルファ標的遺伝子を使用する方法
US8192735B2 (en) 2004-04-13 2012-06-05 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2005099747A1 (en) 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
US20110319324A1 (en) 2005-05-27 2011-12-29 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
JP2009517412A (ja) 2005-11-30 2009-04-30 アンブリリア バイオファーマ インコーポレイテッド アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法
PE20071063A1 (es) 2005-12-20 2007-10-24 Bristol Myers Squibb Co Formulaciones de proteinas estables
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN101854947A (zh) 2007-08-16 2010-10-06 圣文森特医院悉尼有限公司 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
WO2009042798A1 (en) 2007-09-26 2009-04-02 Cold Spring Harbor Laboratory Methods for treating fibrosis by modulating cellular senescence
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
CN101983205B (zh) 2008-03-31 2015-08-19 辉凌公司 催产素类似物
EA021001B1 (ru) 2008-10-24 2015-03-31 Новартис Аг Биосинтетический пирролинкарбоксилизин и сайт-специфичные модификации белка за счет химической модификации остатков пирролинкарбоксилизина и пирролизина
MX2011004427A (es) * 2008-11-05 2011-05-31 Hoffmann La Roche Agonistas del receptor de neuropeptido-2 (y-2r) y usos de los mismos.
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
EP2261662B1 (en) * 2009-06-10 2014-01-22 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Novel synthetic blocking reagents
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP2013516471A (ja) 2010-01-06 2013-05-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 薬物の脂肪酸誘導体および類似体
CN101852804B (zh) 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
DK2563753T6 (en) 2010-04-27 2016-04-04 Synaffix Bv Fused cyclooctynforbindelser and their use in metal-free click-reactions
WO2011134816A1 (en) * 2010-04-27 2011-11-03 Syngenta Participations Ag Methods of controlling neonicotinoid resistant aphids
ES2674567T3 (es) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
WO2013006656A2 (en) 2011-07-05 2013-01-10 The Regents Of The University Of California Appetite stimulating protein
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
KR102057356B1 (ko) 2012-02-27 2019-12-18 아뮤닉스 파마슈티컬스, 인크. Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105073133B (zh) 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
AU2013363768B2 (en) 2012-12-21 2016-02-04 F. Hoffmann-La Roche Ag Peptides as oxytocin agonists
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2015003122A2 (en) 2013-07-03 2015-01-08 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
CN105612173A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状apelin衍生物
WO2015017710A1 (en) 2013-07-31 2015-02-05 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
JP6609563B2 (ja) 2013-11-26 2019-11-20 ノバルティス アーゲー ケトンで修飾されたポリペプチドをオキシム複合化する方法
CN106102775A (zh) 2014-02-07 2016-11-09 效应物治疗公司 治疗纤维变性疾病的方法
WO2015166873A1 (ja) 2014-05-01 2015-11-05 富士フイルム株式会社 赤外線センサ、近赤外線吸収組成物、感光性樹脂組成物、化合物、近赤外線吸収フィルタおよび撮像装置
US20170073406A1 (en) 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US10406198B2 (en) 2014-05-23 2019-09-10 Novartis Ag Methods for making conjugates from disulfide-containing proteins
EA201790051A1 (ru) 2014-06-20 2017-04-28 Авео Фармасьютикалз, Инк. Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170107248A1 (en) 2014-06-23 2017-04-20 Novartis Ag Site specific protein modifications
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
EP3160496B1 (en) 2014-06-24 2021-03-03 Novo Nordisk As Mic-1 fusion proteins and uses thereof
ES2883158T3 (es) 2014-07-30 2021-12-07 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
JP6663428B2 (ja) 2014-10-30 2020-03-11 アクセルロン ファーマ， インコーポレイテッド Ｇｄｆ１５ポリペプチドを使用する、赤血球を増加させるための方法および組成物
AP2017009828A0 (en) 2014-10-31 2017-03-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
WO2016102580A1 (en) 2014-12-22 2016-06-30 Novo Nordisk A/S Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
MA41916A (fr) 2015-04-06 2021-04-14 Acceleron Pharma Inc Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
AU2016246602B2 (en) 2015-04-06 2020-11-19 Acceleron Pharma Inc. Single-arm type I and type II receptor fusion proteins and uses thereof
WO2017066525A1 (en) 2015-10-14 2017-04-20 The Johns Hopkins University Protein bioconjugation method
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
EP3184106A1 (en) 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
WO2017147742A1 (en) 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
AU2017228489A1 (en) 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
KR101727506B1 (ko) 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
JP2020517657A (ja) 2017-04-20 2020-06-18 ノヴォ ノルディスク アー／エス アルブミン融合タンパク質の精製方法
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
CN111163795A (zh) 2017-09-10 2020-05-15 诺沃挪第克公司 用于治疗肥胖症的mic-1和glp-1
EP3934679A1 (en) 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
AU2021254751B2 (en) 2020-04-15 2025-01-30 Theradaptive, Inc. Compositions and methods for targeted therapeutic delivery to bone
WO2022092915A1 (ko) 2020-10-30 2022-05-05 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083505A1 (en) * 2012-11-30 2014-06-05 Novartis Ag Methods for making conjugates from disulfide-containing proteins
WO2015006728A2 (en) * 2013-07-11 2015-01-15 Usera Aimee Site-specific chemoenzymatic protein modifications
WO2015013169A2 (en) * 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015013168A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHAE, S.Y. ; CHOI, Y.G. ; SON, S. ; JUNG, S.Y. ; LEE, D.S. ; LEE, K.C.: "The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 144, no. 1, 21 May 2010 (2010-05-21), AMSTERDAM, NL , pages 10 - 16, XP027036550, ISSN: 0168-3659 *
D. LEFORT, VOROB'EV V. D., SOMOV G. V., NIKISHIN G. I.: "Free-radical addition of alcohols and acids to 10-undecenoic esters, 10-undecen-1-Ol, and 10-undecenyl acetate", BULLETIN OF THE ACADEMY OF SCIENCES OF THE USSR, DIVISION OF CHEMICAL SCIENCES., SPRINGER NEW YORK LLC, US, vol. 16, no. 3, 1 March 1967 (1967-03-01), US , pages 623 - 627, XP055223363, ISSN: 0568-5230, DOI: 10.1007/BF00906006 *
LIM SUNG IN; MIZUTA YUKINA; TAKASU AKINORI; HAHN YOUNG S.; KIM YONG HWAN; KWON INCHAN: "Site-specific fatty acid-conjugation to prolong protein half-lifein vivo", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 170, no. 2, 2 June 2013 (2013-06-02), AMSTERDAM, NL , pages 219 - 225, XP028676591, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2013.05.023 *
MICHAEL J. HACKETT, SHYAMSUNDER JOOLAKANTI, MEGAN E. HARTRANFT, PATRICK C. GULEY, MOO J. CHO: "A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, vol. 101, no. 9, 1 September 2012 (2012-09-01), US , pages 3292 - 3304, XP055223401, ISSN: 0022-3549, DOI: 10.1002/jps.23213 *
OLOF CEDER ET AL.: "Pimaricin. II. High Pressure-High Temperature Hydrogenation Studies", Acta Chemica Scandinavica, 1 January 1964 (1964-01-01), pages 83-97, XP055223487, Retrieved from the Internet: URL:http://actachemscand.org/pdf/acta_vol_18_p0083-0097.pdf [retrieved on 2015-10-26], page 86; compound 2 *
WANG, Q. GRAHAM, K. SCHAUER, T. FIETZ, T. MOHAMMED, A. LIU, X. HOFFEND, J. HABERKORN, U. EISENHUT, M. MIER, W.: "Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate", NUCL. MED. BIOL., ELSEVIER, NY., US, vol. 31, no. 1, 1 January 2004 (2004-01-01), US , pages 21 - 30, XP004485708, ISSN: 0969-8051, DOI: 10.1016/S0969-8051(03)00099-4 *

Also Published As

Publication number Publication date
CY1125006T1 (el) 2023-01-05
TW202039004A (zh) 2020-11-01
RS62907B1 (sr) 2022-03-31
MA40278A (fr) 2017-04-26
UY36186A (es) 2016-01-29
JP6823696B2 (ja) 2021-02-03
BR112016028884A2 (pt) 2017-10-31
SG11201609704TA (en) 2017-01-27
CU24455B1 (es) 2019-11-04
US10786576B2 (en) 2020-09-29
JP2023099133A (ja) 2023-07-11
EA201692466A1 (ru) 2017-04-28
MX2016017395A (es) 2017-05-01
JP2020203934A (ja) 2020-12-24
PT3157571T (pt) 2022-02-14
HK1232160A1 (zh) 2018-01-05
AU2015280351C1 (en) 2022-11-24
CN114099693A (zh) 2022-03-01
HRP20220152T1 (hr) 2022-04-15
HUE057845T2 (hu) 2022-06-28
US11752211B2 (en) 2023-09-12
JP6636959B2 (ja) 2020-01-29
AP2016009585A0 (en) 2016-11-30
JP2017519024A (ja) 2017-07-13
TN2016000558A1 (en) 2018-04-04
ECSP17004665A (es) 2018-11-30
MX367520B (es) 2019-08-26
US20210000964A1 (en) 2021-01-07
TW202204384A (zh) 2022-02-01
CN107073130B (zh) 2021-11-16
IL248990A0 (en) 2017-01-31
DK3157571T3 (da) 2022-02-21
PH12016502294B1 (en) 2022-03-23
ES2905479T3 (es) 2022-04-08
MY193993A (en) 2022-11-07
GT201600263A (es) 2019-07-19
JP7650315B2 (ja) 2025-03-24
TWI701048B (zh) 2020-08-11
AU2015280351A1 (en) 2016-12-08
AU2015280351B2 (en) 2018-07-05
PL3157571T3 (pl) 2022-03-28
JP2022095757A (ja) 2022-06-28
US20240066132A1 (en) 2024-02-29
PH12016502294A1 (en) 2017-02-13
TW201613653A (en) 2016-04-16
KR102559975B1 (ko) 2023-07-27
US10588980B2 (en) 2020-03-17
SI3157571T1 (sl) 2022-04-29
KR20170020878A (ko) 2017-02-24
CL2016003281A1 (es) 2017-06-09
EP3157571A1 (en) 2017-04-26
EP3988170A1 (en) 2022-04-27
IL248990B (en) 2019-09-26
JP7051959B2 (ja) 2022-04-11
CR20160596A (es) 2017-05-08
KR20230056796A (ko) 2023-04-27
JO3813B1 (ar) 2021-01-31
CA2953480A1 (en) 2015-12-30
CN107073130A (zh) 2017-08-18
TWI750725B (zh) 2021-12-21
US20180326079A1 (en) 2018-11-15
PE20171095A1 (es) 2017-08-07
TWI792596B (zh) 2023-02-11
US20160030585A1 (en) 2016-02-04
SG10201912965TA (en) 2020-02-27
CU20160189A7 (es) 2017-04-05
EP3157571B1 (en) 2021-11-24
LT3157571T (lt) 2022-02-25
WO2015200078A8 (en) 2016-04-14
WO2015200078A1 (en) 2015-12-30
JP2019206563A (ja) 2019-12-05
CN114133443A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
US20240066132A1 (en) Novel fatty acids and their use in conjugation to biomolecules
KR102310392B1 (ko) 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
EA027853B1 (ru) Синтетические миметики апелина для лечения сердечной недостаточности
EA030023B1 (ru) Производные эксендина-4 как двойные агонисты glp1/глюкагона
US20180009849A1 (en) Ghrelin analogues
HK40072273A (en) Fatty acids and their use in conjugation to biomolecules
BR112016028884B1 (pt) Conjugado compreendendo uma biomolécula ligada a um ácido graxo, seu uso, mistura, combinação, composição farmacêutica, e composto
HK1232160B (en) Fatty acids and their use in conjugation to biomolecules